×
About 10,387 results

ALLMedicine™ Follicular Lymphoma Center

Research & Reviews  4,725 results

Complete remission of follicular lymphoma after SARS-CoV-2 infection: from the "flare p...
https://doi.org/10.1007/s00259-021-05275-6
European Journal of Nuclear Medicine and Molecular Imaging; Sollini M, Gelardi F et. al.

Feb 27th, 2021 - Complete remission of follicular lymphoma after SARS-CoV-2 infection: from the "flare phenomenon" to the "abscopal effect".|2021|Sollini M,Gelardi F,Carlo-Stella C,Chiti A,|

Microbial dysbiosis is associated with aggressive histology and adverse clinical outcom...
https://doi.org/10.1182/bloodadvances.2020003129
Blood Advances; Diefenbach CS, Peters BA et. al.

Feb 26th, 2021 - B-cell non-Hodgkin lymphoma cell survival depends on poorly understood immune evasion mechanisms. In melanoma, the composition of the gut microbiota (GMB) is associated with immune system regulation and response to immunotherapy. We investigated t...

Tiny but Mighty: Collision Tumor of a Superficial Adenocarcinoma Arising From a Tubulov...
https://doi.org/10.1177/1066896921995942
International Journal of Surgical Pathology; Lin YS, Hamilton AER et. al.

Feb 23rd, 2021 - Collision tumors are rare and there have only been a few previously described cases between an intestinal adenoma and a lymphoma. We report the first case of a 74-year-old woman who on investigation for iron deficiency had a tubulovillous adenoma ...

see more →

Guidelines  31 results

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for...
https://doi.org/10.1016/j.annonc.2020.11.008
Annals of Oncology : Official Journal of the European Soc... Dreyling M, Ghielmini M et. al.

Nov 29th, 2020 - Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Dreyling M,Ghielmini M,Rule S,Salles G,Ladetto M,|

Off-the-shelf CAR-T regimen safe for advanced lymphoma
https://www.healio.com/hematology-oncology/lymphoma/news/online/{87e5706a-8ecb-4473-95b8-60f27a6e22cb}/off-the-shelf-car-t-regimen-safe-for-advanced-lymphoma

May 31st, 2020 - An allogeneic chimeric antigen T-cell therapy plus an anti-CD52 monoclonal antibody appeared safe for certain patients with large B-cell or follicular lymphoma, according to study data presented during the ASCO20 Virtual Scientific Program.

Off-the-Shelf CAR-T Cell Therapy ALLO-501 Induces High Responses in Relapsed/Refractory B-Cell Lymphomas
https://www.onclive.com/conference-coverage/asco-2020/off-the-shelf-cart-cell-therapy-allo501-induces-high-responses-in-relapsed-refractory-bcell-lymphomas

May 29th, 2020 - The allogeneic chimeric antigen receptor (CAR)-T cell therapy ALLO-501, paired with the monoclonal antibody ALLO-647, has clinical activity and a manageable safety profile in patients with relapsed/refractory large B-cell or follicular lymphoma. T...

Novel CAR-T Cell Therapy Combination Shows Preliminary Activity in R/R B-cell Lymphoma
https://www.targetedonc.com/view/novel-car-t-cell-therapy-combination-shows-preliminary-activity-in-r-r-b-cell-lymphoma

May 28th, 2020 - First-in-human findings show that ALLO-501, an allogeneic chimeric antigen receptor (CAR)-T cell therapy plus ALLO-647, a monoclonal antibody, has clinical activity and is tolerable in patients with relapsed/refractory large B-cell or follicular l...

Where does transplant fit in the age of targeted therapies?
https://ashpublications.org/hematology/article-abstract/2019/1/287/422587/Where-does-transplant-fit-in-the-age-of-targeted?redirectedFrom=fulltext
ASH Clinical News; Chow VA,et al

Dec 5th, 2019 - The role of hematopoietic cell transplantation (HCT) for indolent lymphoma has evolved over the last 5 years with the availability of novel low-toxicity therapies and a better understanding of the prognosis of these entities. However, despite nume...

see more →

Drugs  21 results see all →

Clinicaltrials.gov  5,119 results

Complete remission of follicular lymphoma after SARS-CoV-2 infection: from the "flare p...
https://doi.org/10.1007/s00259-021-05275-6
European Journal of Nuclear Medicine and Molecular Imaging; Sollini M, Gelardi F et. al.

Feb 27th, 2021 - Complete remission of follicular lymphoma after SARS-CoV-2 infection: from the "flare phenomenon" to the "abscopal effect".|2021|Sollini M,Gelardi F,Carlo-Stella C,Chiti A,|

Microbial dysbiosis is associated with aggressive histology and adverse clinical outcom...
https://doi.org/10.1182/bloodadvances.2020003129
Blood Advances; Diefenbach CS, Peters BA et. al.

Feb 26th, 2021 - B-cell non-Hodgkin lymphoma cell survival depends on poorly understood immune evasion mechanisms. In melanoma, the composition of the gut microbiota (GMB) is associated with immune system regulation and response to immunotherapy. We investigated t...

ZUMA-5: Axicabtagene Ciloleucel Elicits Response in Indolent Non-Hodgkin Lymphoma
https://ascopost.com/issues/february-25-2021-supplement-conference-highlights-ash-2020/zuma-5-axicabtagene-ciloleucel-elicits-response-in-indolent-non-hodgkin-lymphoma/

Feb 24th, 2021 - In the phase II ZUMA-5 trial, the cellular immunotherapy axicabtagene ciloleucel led to responses in 92% of patients with indolent non-Hodgkin lymphoma (NHL), researchers reported at the 2020 American Society of Hematology (ASH) Annual Meeting & E...

Expert Point of View: James Essell, MD
https://ascopost.com/issues/february-25-2021-supplement-conference-highlights-ash-2020/epov-james-essell/

Feb 24th, 2021 - James Essell, MD, Medical Director of the Blood Cancer Center, The Jewish Hospital-Mercy Health Cincinnati Cancer and Cellular Therapy Center, and Chair of Cellular Therapy, observed that axicabtagene ciloleucel compares favorably with other chime...

see more →

News  489 results

FDA Approves Umbralisib (Ukoniq) for Two Lymphomas
https://www.medscape.com/viewarticle/945426

Feb 7th, 2021 - The US Food and Drug Administration (FDA) has granted accelerated approval to umbralisib (Ukoniq) for the treatment of adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and...

First Data for CAR T-cell Therapy in Follicular Lymphoma: ZUMA-5
https://www.medscape.com/viewarticle/942494

Dec 10th, 2020 - For the first time, a chimeric antigen receptor (CAR) therapy has yielded a high response rate among patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), including patients with follicular lymphoma (FL) and marginal zone lymphom...

First-in-Class Oral EZH2 Inhibitor Effective in Two Cancers
https://www.staging.medscape.com/viewarticle/939347

Oct 18th, 2020 - Tazemetostat (Tazverik) showed potential for improving outcomes for patients with advanced or metastatic epithelioid sarcoma and also yielded clinically meaningful responses in heavily pretreated patients with follicular lymphoma. The findings com...

First-in-Class Oral EZH2 Inhibitor Effective in Two Cancers
https://www.medscape.com/viewarticle/939347

Oct 18th, 2020 - Tazemetostat (Tazverik) showed potential for improving outcomes for patients with advanced or metastatic epithelioid sarcoma and also yielded clinically meaningful responses in heavily pretreated patients with follicular lymphoma. The findings com...

see more →

Patient Education  2 results see all →